Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement

Sep

19

Today In Oncology

Losing Weight and Breast Cancer Risk? The GLP-1 Question

TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer

NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer

Advertisement

© 2026 HSP News Service, L.L.C.